Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer.

Saigi M, Alburquerque-Bejar JJ, McLEER-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Cancer Res. 2018 Jun 13. pii: clincanres.0267.2018. doi: 10.1158/1078-0432.CCR-18-0267. [Epub ahead of print]

PMID:
29898990
2.

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14.

PMID:
29139039
3.

Retraction: Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.

Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, Serrano M.

Nature. 2017 Jul 12;547(7662):246. doi: 10.1038/nature23287.

PMID:
28703201
4.

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.

Gimenez-Xavier P, Pros E, Bonastre E, Moran S, Aza A, Graña O, Gomez-Lopez G, Derdak S, Dabad M, Esteve-Codina A, Hernandez Mora JR, Salinas-Chaparro D, Esteller M, Pisano D, Sanchez-Cespedes M.

Mol Cancer Ther. 2017 Jul;16(7):1366-1376. doi: 10.1158/1535-7163.MCT-17-0104. Epub 2017 Apr 10.

5.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

6.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

7.

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.

Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J.

Oncotarget. 2016 Nov 22;7(47):77378-77388. doi: 10.18632/oncotarget.12671.

8.

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.

Romero OA, Verdura S, Torres-Diz M, Gomez A, Moran S, Condom E, Esteller M, Villanueva A, Sanchez-Cespedes M.

Oncogene. 2017 Mar 2;36(9):1287-1296. doi: 10.1038/onc.2016.296. Epub 2016 Sep 5.

PMID:
27593925
9.

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF.

Oncogene. 2016 Sep 29;35(39):5179-90. doi: 10.1038/onc.2016.50. Epub 2016 Mar 21.

PMID:
26996667
10.

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M.

Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.

PMID:
26855149
11.

Cell adhesion and polarity in squamous cell carcinoma of the lung.

Bonastre E, Brambilla E, Sanchez-Cespedes M.

J Pathol. 2016 Apr;238(5):606-16. doi: 10.1002/path.4686. Epub 2016 Feb 29. Review.

PMID:
26749265
12.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

13.

PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Bonastre E, Verdura S, Zondervan I, Facchinetti F, Lantuejoul S, Chiara MD, Rodrigo JP, Carretero J, Condom E, Vidal A, Sidransky D, Villanueva A, Roz L, Brambilla E, Savola S, Sanchez-Cespedes M.

Cancer Res. 2015 Apr 1;75(7):1287-97. doi: 10.1158/0008-5472.CAN-14-2444.

14.

Expression inactivation of SMARCA4 by microRNAs in lung tumors.

Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M, Reyes-Zurita FJ, Lupiáñez JA, Sánchez-Cespedes M, Slack FJ, Medina PP.

Hum Mol Genet. 2015 Mar 1;24(5):1400-9. doi: 10.1093/hmg/ddu554. Epub 2014 Oct 29.

15.

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.

Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A.

Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12.

16.

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.

Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.

17.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

18.

The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases.

Romero OA, Sanchez-Cespedes M.

Oncogene. 2014 May 22;33(21):2681-9. doi: 10.1038/onc.2013.227. Epub 2013 Jun 10. Review.

PMID:
23752187
19.

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.

Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M.

Int J Cancer. 2013 Aug 15;133(4):898-907. doi: 10.1002/ijc.28090. Epub 2013 Mar 9.

20.

UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status.

Pallante P, Malapelle U, Berlingieri MT, Bellevicine C, Sepe R, Federico A, Rocco D, Galgani M, Chiariotti L, Sanchez-Cespedes M, Fusco A, Troncone G.

Eur J Cancer. 2013 Mar;49(5):1117-26. doi: 10.1016/j.ejca.2012.09.033. Epub 2012 Oct 24.

PMID:
23102841
21.

Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Maraver A, Fernández-Marcos PJ, Herranz D, Muñoz-Martin M, Gomez-Lopez G, Cañamero M, Mulero F, Megías D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M.

Cancer Cell. 2012 Aug 14;22(2):222-34. doi: 10.1016/j.ccr.2012.06.014.

22.

The SOX family of genes in cancer development: biological relevance and opportunities for therapy.

Castillo SD, Sanchez-Cespedes M.

Expert Opin Ther Targets. 2012 Sep;16(9):903-19. doi: 10.1517/14728222.2012.709239. Epub 2012 Jul 26. Review.

PMID:
22834733
23.

EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours.

Bornachea O, Santos M, Martínez-Cruz AB, García-Escudero R, Dueñas M, Costa C, Segrelles C, Lorz C, Buitrago A, Saiz-Ladera C, Agirre X, Grande T, Paradela B, Maraver A, Ariza JM, Prosper F, Serrano M, Sánchez-Céspedes M, Paramio JM.

Sci Rep. 2012;2:434. doi: 10.1038/srep00434. Epub 2012 May 31.

24.

The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer.

Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M.

EMBO Mol Med. 2012 Jul;4(7):603-16. doi: 10.1002/emmm.201200236. Epub 2012 Apr 11.

25.

Epigenetic disruption of cadherin-11 in human cancer metastasis.

Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M.

J Pathol. 2012 Oct;228(2):230-40. doi: 10.1002/path.4011. Epub 2012 Jul 26.

26.

Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer.

Castillo SD, Matheu A, Mariani N, Carretero J, Lopez-Rios F, Lovell-Badge R, Sanchez-Cespedes M.

Cancer Res. 2012 Jan 1;72(1):176-86. doi: 10.1158/0008-5472.CAN-11-3506. Epub 2011 Nov 14.

27.

A DNA methylation fingerprint of 1628 human samples.

Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, Monk D, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C, Esteller M.

Genome Res. 2012 Feb;22(2):407-19. doi: 10.1101/gr.119867.110. Epub 2011 May 25.

28.

The role of LKB1 in lung cancer.

Sanchez-Cespedes M.

Fam Cancer. 2011 Sep;10(3):447-53. doi: 10.1007/s10689-011-9443-0. Review.

PMID:
21516316
29.

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.

Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, Sanchez-Verde L, Pisano DG, Sanchez-Cespedes M.

Hum Mutat. 2011 Feb;32(2):E1999-2017. doi: 10.1002/humu.21415. Epub 2010 Dec 7.

PMID:
21280140
30.

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.

J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. Review.

31.

Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer.

López-Encuentra A, López-Ríos F, Conde E, García-Luján R, Suárez-Gauthier A, Mañes N, Renedo G, Duque-Medina JL, García-Lagarto E, Rami-Porta R, González-Pont G, Astudillo-Pombo J, Maté-Sanz JL, Freixinet J, Romero-Saavedra T, Sánchez-Céspedes M, Gómez de la Camara A; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).

Eur Respir J. 2011 Jan;37(1):136-42. doi: 10.1183/09031936.00028610. Epub 2010 Sep 3.

32.

The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.

Conde E, Angulo B, Redondo P, Toldos O, García-García E, Suárez-Gauthier A, Rubio-Viqueira B, Marrón C, García-Luján R, Sánchez-Céspedes M, López-Encuentra A, Paz-Ares L, López-Ríos F.

PLoS One. 2010 Aug 17;5(8):e12209. doi: 10.1371/journal.pone.0012209.

33.

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M.

J Pathol. 2010 Sep;222(1):89-98. doi: 10.1002/path.2732.

PMID:
20556744
34.

Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells.

Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T, Yokota J.

Lung Cancer. 2010 Nov;70(2):136-45. doi: 10.1016/j.lungcan.2010.02.004. Epub 2010 Mar 5.

PMID:
20207041
35.

A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.

Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J.

Genes Chromosomes Cancer. 2010 Apr;49(4):342-52. doi: 10.1002/gcc.20746.

36.

Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma.

Moral M, Segrelles C, Martínez-Cruz AB, Lorz C, Santos M, García-Escudero R, Lu J, Buitrago A, Costa C, Saiz C, Ariza JM, Dueñas M, Rodriguez-Peralto JL, Martinez-Tello FJ, Rodriguez-Pinilla M, Sanchez-Cespedes M, Digiovanni J, Paramio JM.

In Vivo. 2009 Sep-Oct;23(5):653-60.

37.

A gene-alteration profile of human lung cancer cell lines.

Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, Montuenga LM, Minna JD, Yokota J, Sanchez-Cespedes M.

Hum Mutat. 2009 Aug;30(8):1199-206. doi: 10.1002/humu.21028.

38.

Lung cancer biology: a genetic and genomic perspective.

Sánchez-Céspedes M.

Clin Transl Oncol. 2009 May;11(5):263-9. Review.

PMID:
19451058
39.

[Prognostic value study of lung cancer molecular markers].

García Luján R, Conde Gallego E, López Ríos F, Martín De Nicolás JL, Sánchez Céspedes M, García Quero C, López Encuentra A.

Med Clin (Barc). 2009 Apr 18;132(14):529-36. doi: 10.1016/j.medcli.2008.10.060. Epub 2009 Apr 14. Spanish.

PMID:
19368933
40.

Analysis of the molecular expression profile of non small cell lung carcinoma associated to chronic obstructive pulmonary disease.

Garcia-Lujan R, Conde-Gallego E, Lopez-Ríos F, Martin de Nicolas JL, Sanchez-Céspedes M, García-Quero C, Echave-Sustaeta JM, Lopez-Encuentra A.

Histol Histopathol. 2009 Apr;24(4):417-23. doi: 10.14670/HH-24.417.

PMID:
19224444
41.

BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer.

Rodriguez-Nieto S, Sanchez-Cespedes M.

Carcinogenesis. 2009 Apr;30(4):547-54. doi: 10.1093/carcin/bgp035. Epub 2009 Jan 28. Review.

PMID:
19176640
42.

Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Moral M, Segrelles C, Lara MF, Martínez-Cruz AB, Lorz C, Santos M, García-Escudero R, Lu J, Kiguchi K, Buitrago A, Costa C, Saiz C, Rodriguez-Peralto JL, Martinez-Tello FJ, Rodriguez-Pinilla M, Sanchez-Cespedes M, Garín M, Grande T, Bravo A, DiGiovanni J, Paramio JM.

Cancer Res. 2009 Feb 1;69(3):1099-108. doi: 10.1158/0008-5472.CAN-08-3240. Epub 2009 Jan 27.

43.

The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.

Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers HC, Cigudosa JC, Lazo PA, Sanchez-Cespedes M.

Hum Mol Genet. 2009 Apr 1;18(7):1343-52. doi: 10.1093/hmg/ddp034. Epub 2009 Jan 19.

PMID:
19153074
44.

The impact of gene expression microarrays in the evaluation of lung carcinoma subtypes and DNA copy number.

Sanchez-Cespedes M.

Arch Pathol Lab Med. 2008 Oct;132(10):1562-5. doi: 10.1043/1543-2165(2008)132[1562:TIOGEM]2.0.CO;2. Review.

PMID:
18834210
45.

A microRNA DNA methylation signature for human cancer metastasis.

Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61. doi: 10.1073/pnas.0803055105. Epub 2008 Sep 3.

46.

Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.

Medina PP, Sanchez-Cespedes M.

Epigenetics. 2008 Mar-Apr;3(2):64-8. Epub 2008 Apr 17. Review. Erratum in: Epigenetics. 2008 Jul-Aug;3(4):234. Cespedes, Montse Sanchez [corrected to Sanchez-Cespedes, Montse].

PMID:
18437052
47.

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M.

Hum Mutat. 2008 May;29(5):617-22. doi: 10.1002/humu.20730.

PMID:
18386774
48.

Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.

Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M.

J Pathol. 2008 Feb;214(3):347-56.

PMID:
17992665
49.

Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas.

Valbuena A, Suárez-Gauthier A, López-Rios F, López-Encuentra A, Blanco S, Fernández PL, Sánchez-Céspedes M, Lazo PA.

Lung Cancer. 2007 Dec;58(3):303-9. Epub 2007 Aug 8.

PMID:
17689819
50.

A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.

Sanchez-Cespedes M.

Oncogene. 2007 Dec 13;26(57):7825-32. Epub 2007 Jun 18. Review.

PMID:
17599048

Supplemental Content

Loading ...
Support Center